A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Niraparib Oral Product
Sponsor: Institut Paoli-Calmettes
Collaborators: GlaxoSmithKline